Interim results of a post-marketing surveillance of ponatinib

Kiyohiko Hatake

Presentation information

Oral Session

Oral Session 2-9B CML: Clinical trials

Sat. Oct 13, 2018 10:10 AM - 11:10 AM No.9 (Osaka International Convention Center, 10F 1008)

Chair: Chikashi Yoshida (Department of Hematology, National Hospital Oganization Mito Medical Center, Japan)

【Ｅ】

[OS2-9B-5] Interim results of a post-marketing surveillance of ponatinib

Kiyohiko Hatake^1,2,3,4,5, Takahiro Yoshida², Moriyoshi Yasuda³, Mihoko Ota³, Akira Masunari³, Yasuhiko Fukuta³, Yuji Ikari⁴, Arinobu Tojo⁵ (1.Hematology, International University of Health and Welfare,Tokyo, Japan, 2.Medical Affairs, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan, 3.Pharmacovigilance, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan, 4.Tokai University School of Medicine, Kanagawa, Japan, 5.The Institute of Medical Science, The University of Tokyo, Japan)

Abstract password authentication.
Password is written on a program and abstract book.